INTRODUCTION: Selected patients with isolated breast cancer liver metastases (BCLM) may benefit from surgical management; however, indications remain unclear and the risks may outweigh the benefits in patients with a generally poor prognosis. METHODS: Between 1998 and 2006, 17 patients diagnosed with BCLM were considered for surgical management (<4 tumours, tumour <4 cm in diameter and no/stable extrahepatic metastases). Peri-operative and outcomes data were analysed and compared. RESULTS: Eight patients were found to have extensive or untreatable disease on staging laparoscopy and intra-operative ultrasound (SL/IOUS). The remaining nine patients underwent surgical management [seven laparoscopic radiofrequency ablations (RFA) and two hepatic resections]. Median length of follow-up for patients treated surgically was 40.0 months, median disease-free survival (DFS) was 32.2 months and median time to disease progression was 17.7 months. Of the eight patients not amenable to surgery, median length of follow-up was 21.8 months. CONCLUSION: SL/IOUS prevented unnecessary laparotomy in half of the patients taken to the operating room for surgical treatment of BCLM. In patients with BCLM, SL/IOUS should be considered standard of care before surgical intervention. The small number of patients and short follow-up may be inadequate to determine the true value of surgical management in this group of patients with BCLM.
INTRODUCTION: Selected patients with isolated breast cancer liver metastases (BCLM) may benefit from surgical management; however, indications remain unclear and the risks may outweigh the benefits in patients with a generally poor prognosis. METHODS: Between 1998 and 2006, 17 patients diagnosed with BCLM were considered for surgical management (<4 tumours, tumour <4 cm in diameter and no/stable extrahepatic metastases). Peri-operative and outcomes data were analysed and compared. RESULTS: Eight patients were found to have extensive or untreatable disease on staging laparoscopy and intra-operative ultrasound (SL/IOUS). The remaining nine patients underwent surgical management [seven laparoscopic radiofrequency ablations (RFA) and two hepatic resections]. Median length of follow-up for patients treated surgically was 40.0 months, median disease-free survival (DFS) was 32.2 months and median time to disease progression was 17.7 months. Of the eight patients not amenable to surgery, median length of follow-up was 21.8 months. CONCLUSION:SL/IOUS prevented unnecessary laparotomy in half of the patients taken to the operating room for surgical treatment of BCLM. In patients with BCLM, SL/IOUS should be considered standard of care before surgical intervention. The small number of patients and short follow-up may be inadequate to determine the true value of surgical management in this group of patients with BCLM.
Authors: Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Giovanni Ramacciato; Matteo Cescon; Giovanni Varotti; Massimo Del Gaudio; Gaetano Vetrone; Antonio Daniele Pinna Journal: Ann Surg Oncol Date: 2005-05-05 Impact factor: 5.344
Authors: X He; Q Zhang; Y Feng; Z Li; Q Pan; Y Zhao; W Zhu; N Zhang; J Zhou; L Wang; M Wang; Z Liu; H Zhu; Z Shao; L Wang Journal: Clin Transl Oncol Date: 2019-06-22 Impact factor: 3.405
Authors: Aldrick Ruiz; Mylène Sebagh; Dennis A Wicherts; Carlos Castro-Benitez; Richard van Hillegersberg; Bernard Paule; Denis Castaing; Eric Vibert; Antonio Sa Cunha; Daniel Cherqui; Jean-François Morère; René Adam Journal: Breast Cancer Res Treat Date: 2018-02-20 Impact factor: 4.872
Authors: Alan I Valderrama-Treviño; Baltazar Barrera-Mera; Jesús C Ceballos-Villalva; Eduardo E Montalvo-Javé Journal: Euroasian J Hepatogastroenterol Date: 2017-09-29